The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Aiming to expedite drug development, enhance the body of clinical evidence supporting new and existing therapies, and improve ...

Clark, Executive Director, Patient Innovation & Engagement, Global Medical and Scientific Affairs at Merck, about the ...

Early results of a real-world study of faricimab demonstrated sustainable improvements in visual acuity and retinal anatomic ...

The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...

Synchron also reported evidence the device worked in the six-patient trial, with the conversion of brain signals to motor ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, ...

Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of ...